Monthly Archives: April 2021

ASU grad inspired by fatherhood to research child development – ASU Now

Posted: April 21, 2021 at 9:45 am

April 19, 2021

Editor's note:This story is part of a series of profiles ofnotable spring 2021 graduates.

Natalee Lauro is no stranger to difficult times. She was diagnosed with brain cancer at the young age of 8. Photo courtesy of Natalee Lauro Download Full Image

The entire process was very depressing, painful and sometimes just completely soul-crushing," she said. "My social worker helped me through these difficult times and that is when I realized when I grew up, I wanted to be a social worker and help others just like those who helped me throughout my cancer and recovery experience.

A first-generation graduate, Lauro is well on her way to make those dreams come true. She is graduating this spring with a major in sociology and a minor in communication.

Besides having a passion for helping others, she is also an avid animal lover. She is a firm believer that having a therapy dog during her recovery from brain surgery truly saved her life.

I remember being stuck in the NICU and I couldnt even open my eyes or pick up my head. One day, they brought a therapy dog in and she climbed into my bed. As soon as I felt that warm, furry body, I knew exactly what it was and I really think that was the turning point in my life because after that I started to progress. That is a big reason why Im so passionate about animals.

Lauro says she has really enjoyed her time at ASU and appreciates all the help and guidance given to her. She plans to continue to get her masters degree through ASU in order to give back to the community, help others and strive to make a difference in the world. She shared a bit more of her experience by answering a few questions.

Question: Whats something you learned while at ASU in the classroom or otherwise that surprised you or changed your perspective?

Answer: I will say that during my time at ASU, I have learned a lot about myself and what I am capable of. It has always been my habit to underestimate and doubt myself. Throughout my many accomplishments at ASU, Ive realized that I am capable of so much more than I give myself credit for.

Q: Why did you choose ASU?

A: I chose ASU for its outstanding reputation and for all the great things I have heard through my friends, teachers and members of the family.

Q: As an ASU Online student, what ASU resources did you take advantage of and find most helpful on your journey to completing your degree?

A: I personally found having a success coach, along with an academic adviser, Lisa Barth, the most helpful. As an incoming online student I was worried that I wouldnt have a support system; I was nervous and fearful that I would be seen as just another number on the board. But I was pleasantly surprised to find how strong of a connection I was able to form with my success coach and how supportive and helpful my academic adviser was, together they both guided and steered me through my journey at ASU.

Q: Which professor taught you the most important lesson while at ASU?

A: Each one of my professors taught me unique and individual lessons that collectively all ring true and overall contribute into my work ethic, and that is to ask for help when needed, dont sit there in silence because fear or shame hinders you. You must be brave and bold enough to ask for yourself, because no one else will.

Q: Whats the best piece of advice youd give to those still in school?

A: There is a quote I refer to: Mistakes are proof that I am trying." No one is perfect; we all make mistakes, but that is part of the educational journey thats part of life.

Q: What was your favorite spot for power studying?

A: My bedroom or the office is where I spent my time studying; secluded and quiet places are what helps me the most when studying.

Q: If someone gave you $40 million to solve one problem on our planet, what would you tackle?

A: I would tackle an issue that I am very passionate about and that is animal abuse. I love animals with all my heart and the thought of an animal being mistreated or neglected is enough to make me sick to my stomach. If someone gave me $40 million to solve this problem, all the money would go towards protecting animals, both domestic and wild.

See the article here:

ASU grad inspired by fatherhood to research child development - ASU Now

Posted in Jordan Peterson | Comments Off on ASU grad inspired by fatherhood to research child development – ASU Now

How Prince Philip was turned into a pawn in the phoney culture wars – The Guardian

Posted: at 9:45 am

Once, Richard Thomass Jerry Springer the Opera, to which I contributed unpopular elements, held the TV hate record, with 62,000 complaints. But last week it was out-hated by the BBCs saturation coverage of Prince Philips death, which didnt even win four Olivier awards and had no singing coprophiles. BBC appeasements of unappeasable bad faith actors backfire reliably. More than 110,000 people, missing EastEnders under lockdown, protested the all-channel mourning. That said, the complaints of our day were proper complaints, etched on to stone tablets and delivered by pigeons, not these e-posts they have now which any idiot can send. Indeed, it turns out that 116 of the people complaining were complaining that it was too easy to complain.

It is sad that an old lady has lost her companion of 73 years, grieving alone. And the supposedly controversial comments made by Prince Philip, that critics foregrounded, arent that bad, given that he was born 100 years ago and left normal life for the ermine cocoon of royalty in 1947. No one would expect Rip Van Winkle to wake up and understand the complex terminology of 21st-century transgender rights. Sadly, the duke was too far ahead of the zeitgeist to be declared a warrior of anti-wokeness and get a lucrative book deal. But only just.

The Daily Mail columnist Sarah Vines agenda-setting tribute last week showed how the most tragic and personal event can be press-ganged into the Conservatives fabricated culture war. Though the duke was forbidden from expressing his own opinions in life, Vine has grafted hers on to him in death, riding his memory towards the hell of her own choosing, a Pale Horsewoman of the Apocalypse astride Bernie Cliftons ostrich.

For Vine, Prince Philips passing represented, more than the end of a single life; it represents the end of an era. Of a set of values and personal qualities that seem to have less and less and less place in the modern world; a kind of joyous, unapologetic masculinity that nowadays would and routinely is described by many as toxic. For Vine, the unwitting Duke of Edinburgh is a symbol of that most oppressed minority of all men! Unwilling to let the Jordan Peterson of carriage-driving rest unmolested, Vine goes on.

The thing that always struck me as so wonderful about Prince Philip was the fact that he was unequivocally and unapologetically a bloke. It wasnt only his tendency to put his foot in it. He lived simply and practically, never happier than when barbecuing sausages in the rain on a hillside in Scotland, and then putting those sausages into his mouth, the mouths of his family, or the mouths of delighted passersby. Or doing something complicated with a sausage. In other words, he knew what it meant to be a man. A real, grown-up man. And that, Im afraid, makes him a rare gem in this day and age, when women are encouraged to consider even the offer of a sausage as an act of patriarchal micro-aggression. But you cant fight nature. Or sausages. Men like him are as rare as genuine imported European sausages these days, because the modern world seems to despise them, and sausages, so much. How many young men growing up today, their minds addled with crazy brain powders, their Fairy Liquid hands as soft as their woke faces, even like sausages? Sausages that society no longer treats as treats but as toxins, that require the sternest eradication at the hands of the Commissars of Woke. But if toxic masculinity is loyalty, duty, courage, wisdom and sausages, so be it. Farewell then, Prince Philip, Prince among men, Duke of Sausage. Aw! Truly, this man was the Wokefinder General!

Vines fixation on the dukes admiration for sausage holds water. His pet name for the Queen was sausage. But Vines assertion that the duke channels the same masculine power that high-school incels claim they are denied is a stretch. If we look closely at the dukes politically incorrect gaffes they suggest instead both a self-aware literary meta-commentary on his own persona, and a tentative embracing of woke values. Taken in isolation, the dukes quip, If you stand here much longer youll go home with slitty eyes, to an English student in China in 1986, seems ill-judged. But two months later, to an English student in the Amazon basin, he said: If you stand here much longer you will come home with a working knowledge of the shamanic properties of the ayahuasca root. And a year earlier, to an English student in the Australian outback, he said: If you stand here much longer you will come home able to make complex topographical mental maps by singing tunes in which microtonal shifts in pitch represent the rising and falling of contours. And chuck spears! The duke displayed both a woke sensitivity to indigenous traditions, and a woke awareness of the obsolescence of his colonialist obligations.

The anti-woke infotainer Andrew Neil had hoped to use the duke as an avatar of anti-wokeness on his new anti-woke GB news show, Woke Watch. Neil denies knowing who I am online, as anti-woke Peter denied the woken Christ, but in reality I know the Weetabix-tonsured Wokefinder well. After the duke passed, Wheat-Head Zoomed me an Olivier award-winning theatre director, remember for artistic advice.

Leapy my old friend, Bisc-hair blabbed, the comedy agency Blue Book Artist Management, who are also working the anti-woke market, reckoned they could get me the duke to mock the woke weekly. I dont want to have to use Laurence Fox, although it would be cheaper. Do you think one could animate a hologram of Prince Philips head, like Patrick Moore on Gamesmaster? Yes Andy, I replied, then you could just make the Duke of Edinburgh say whatever you wanted him to say.

A physical media 12 of the January No 1 hit single Comin Over Here by Asian Dub Foundation (ft Stewart Lee) is now available from Xray Productions. The acclaimed anti-rockumentary King Rocker (ft Stewart Lee) is streaming on Now TV

Go here to read the rest:

How Prince Philip was turned into a pawn in the phoney culture wars - The Guardian

Posted in Jordan Peterson | Comments Off on How Prince Philip was turned into a pawn in the phoney culture wars – The Guardian

Drew Hayden Taylor explores everything from the weird and wacky to the deep and profound ways Indigenous Peoples impact the world in – Anishinabek…

Posted: at 9:45 am

Drew Hayden Taylor. Photo supplied

TORONTO Sam Karney (A Life on the Line) and Andrew Wiens (A Life on the Line) of Ice River Films are pleased to announce that the IndigiGonzo series, Going Native, starring Drew Hayden Taylor (Cottagers & Indians, Searching for Winnetou, Mixed Blessings) will premiere on Canadas national Indigenous network APTN. The half-hour, 13-episode series premieres Saturday, May 8, 2021.

In Going Native, celebrated Anishinaabe humorist and author Drew Hayden Taylor turns his comic gaze on how Indigenous Peoples have changed the world and are re-shaping their culture in the 21st century. Each episode takes on one theme, from pop culture to architecture, as Drew takes viewers on a wild journey of discovery from concert halls to desert ruins and from video game conventions to treacherous cliff pole-fishing expeditions.

Every episode is its own unique adventure and Drews perspective ties it together. When people think about Indigenous buildings, they think about teepees, longhouses and wigwams. But Drew Hayden Taylor is thinking about the revolutionary architects that are creating zero-emission communities on the West Coast. When people think about Indigenous food, they think about pemmican and seal blubber; but Drew is tucking into nouveau cuisine in downtown Toronto and learning how traditional companion planting of crops is revolutionizing todays agriculture. When people think about Indigenous culture, they think about beads and dancing, while Drew is watching zombie movies and checking out graffiti artists.

Written by Drew Hayden Taylor, Kurt Spenrath and Paul Kemp, Going Native is directed by Sam Karney, Paul Kemp (Cottagers & Indians, Searching for Winnetou), Andrew Wiens, and Kurt Spenrath (Queen of the Oil Patch). Produced by Sam Karney, Andrew Wiens, and Kurt Spenrath, and executive produced by Paul Kemp of Paul Kemp Productions and Drew Hayden Taylor.

I have always felt this kind of series was sorely needed in the Indigenous community. If you look at a lot of the literature and media about our communities, the focus always seems to be on the negative, or perhaps more accurately the dark, depressing, sad, bleak, and angry perspective of Indigenous life, says writer/producer/host Drew Hayden Taylor. As somebody whos travelled to over 150 First Nation communities, I know for a fact that there is so much more to us. Just down the road and across the field theres laughter, theres beauty, theres the unexpected, and theres the knowledge nobody knows about. Well, maybe we knew, but not everybody did. And that is where the fun begins.

Going Native has been commissioned and financed by APTN, with financial contributions also coming from The Canada Media Fund, Manitoba Film and Music and Ontario Creates.

-30-

ABOUT DREW HAYDEN TAYLOR

Drew Hayden Taylor is an award-winning playwright, novelist, journalist and filmmaker. Born and living on the Curve Lake First Nation (Anishinaabe) in Ontario, he has done everything from stand-up comedy at the Kennedy Centre in Washington D.C. to serving as artistic director of Native Earth Performing Arts, Canadas leading Indigenous theatre company. The author of 33 books, Drew likes to travel the world, spreading the gospel of Native literature and storytelling.

ABOUT ICE RIVER FILMS

Ice River Films was established in Winnipeg in 2013 by Sam Karney and Andrew Wiens to pursue a passion for storytelling through the lens of documentary filmmaking. Propelled by early work in short film for CBC and Bell MTS, their first hour-long documentary, A Life on the Line (APTN), explored Sams Mtis roots and family tradition of working a trap line. Travelling the world, the duo has since worked on several docuseries including, High Maintenance (Smithsonian Canada), Polar Bear Town (Smithsonian US), Taken (APTN/CBC) and First Contact (S02, APTN). Their latest, Going Native (APTN), is hosted by Drew Hayden Taylor.

ABOUT PAUL KEMP PRODUCTIONS

Paul Kemp Productions is a multiple award-winning TV series and feature documentary film company based in Toronto. With over 50 films and series produced over the years, and with sales in over 140 countries, some of the companys notable productions include: Searching for Winnetou (CBC), Transformer (CBC, Netflix USA), The Rise of Jordan Peterson (CBC, SKY UK, Amazon), Village of the Missing (CBC, Sundance Now), Cottagers & Indians (CBC), The Science of Sin (Discovery International), Rise of the Trolls (Amazon + 80 countries) and Infestation (UKTV, ZDF-GERMANY).

ABOUT APTN

APTN launched in 1999 as the worlds first national Indigenous broadcaster, creating a window into the remarkably diverse mosaic of Indigenous Peoples. A respected non-profit and charitable broadcaster, its the only one of its kind in North America. The network is Sharing Our Stories of authenticity in English, French and a variety of Indigenous languages to over 10 million Canadian subscribers. With over 80% Canadian content, APTN connects with its audiences through genuine, inspiring and engaging entertainment on multiple platforms.

Media Contact:Cynthia AmsdenRoundstone CommunicationTelephone: 416.910.7740cynthia@roundstonepr.com

View post:

Drew Hayden Taylor explores everything from the weird and wacky to the deep and profound ways Indigenous Peoples impact the world in - Anishinabek...

Posted in Jordan Peterson | Comments Off on Drew Hayden Taylor explores everything from the weird and wacky to the deep and profound ways Indigenous Peoples impact the world in – Anishinabek…

Texans would rather have a celeb grenade like McConaughey as gov than the same old politics and thats alright, alright, alright – RT

Posted: at 9:45 am

A new poll shows that actor Matthew McConaughey, who has mentioned a potential jump into politics, has far more support in his state to run for governor than the currently-elected Republican.

In a poll released Sunday by The Dallas Morning News and University of Texas at Tyler, 45% of registered Texan voters wouldnt mind the guy most well known for saying, alright, alright, alright as their next governor.

Republican Governor Greg Abbott, on the other hand, received only 33% support in the poll. Broken down by party lines, it becomes clearer that McConaugheys popularity on the screen also likely recent interviews touching on cultural subjects like political correctness outshines any experience Abbott or others bring to the job.

Among Republicans, 56% said they would support a McConaughey run to lead the Lone Star state, while just 30% threw their weight behind Abbott.

For Democrats, 66% support the Dazed and Confused star, while a mere 8% would want Abbott in for another round.

The poll is good news for McConaughey, who recently mentioned a potential future in politics as he appears to be slowing down in his acting career to pursue other opportunities he released a memoir last year.

Its a true consideration, he said of the potential run for governor, saying hes balancing what his leadership role is in the future to his home state.

The little that is known about McConaughey politically has mainly earned him ire from the left, as hes targeted both political parties and called out condescending Hollywood liberals in recent chats. His non-PC friendliness combined with his relationship to folks like Jordan Peterson (aka Red Skull, apparently) has already inspired waves of social justice warriors to warn the Austin resident to check his white privilege as they attempt to tie him to the most extreme version of conservatives painted by the mainstream media.

If McConaughey does choose to run and he continues his push as a self-described moderate, he will find quickly there is no grey area in modern American politics. Youre on one side or the other, and if you refuse to cancel someone like Peterson, your side has already been decided for you.

For now, however, McConaughey has the same wild card celebrity appeal that many public figures have when they jump into politics, Donald Trump included. Not knowing the mans specific positions, but admiring his more broad, straightforward approach to subjects is something voters are craving more and more as approval ratings for lawmakers in Congress continue to be abysmal.

Trump may have lost in 2020, but he also received more votes than any incumbent president ever. Like it or not, the mans brash style and penchant for theater mastered over decades in television and in front of cameras gave him an appeal against the same-old, same-old, well-groomed politicians were so used to seeing slide in and out of office.

Like Trump, McConaughey is a political grenade. Success or failure, hes different and sure to shake up a system that, quite frankly, needs some shaking up, especially when you consider the current president is staring down the barrel of 80 and already served as vice president in the very administration that arguably created the void Trump capitalized on to win the presidency in 2016.

McConaughey is not the only celebrity who has mentioned politics as a serious consideration in the post-Trump era. Former Trump supporter Caitlyn Jenner is reportedly looking at challenging Governor Gavin Newsom in California, and others have mentioned interests in representing their home states, like the Trump-supporting Kid Rock (Michigan).

It may sound crazy to hand the keys of the castle to a bunch of reality television stars and entertainers, but this is how out of touch politicians have become. People identify more with a frustrated celebrity bucking woke trends than anyone who can bring vague experience to the job.

One can argue this is a bad thing and just further chaos, but only a few months of the Biden administration has already shown us the reliability career politicians have. The current president has spent his first weeks racking up massive bills, completely fumbling on the immigration crisis at the border, and he even pushed the deadline for US troops to leave Afghanistan (something that likely is only even being considered by this administration because Trump pushed them into a corner with his peace deal).

The role of politician is not some sacred role to be worshipped, but thats the place weve reached with many modern representatives, who act as celebrities in their own right, cashing big government checks, spending half their time on cable news, and promising the same things over and over, and not delivering.

Its this disappointment that led to Trump, and its this disappointment that will likely lead to a Gov. McConaughey, if we ever see the day he decides to run. That disappointment, however, is not a bad thing. Either PC-hating figures like McConaughey can bring some positive changes to politics, or they can at least remind those sitting comfortably in their offices to not get too comfortable because their jobs can be done by anybody, even the ex-star of Texas Chainsaw Massacre: The Next Generation.

If you like this story, share it with a friend!

The statements, views and opinions expressed in this column are solely those of the author and do not necessarily represent those of RT.

Read the original post:

Texans would rather have a celeb grenade like McConaughey as gov than the same old politics and thats alright, alright, alright - RT

Posted in Jordan Peterson | Comments Off on Texans would rather have a celeb grenade like McConaughey as gov than the same old politics and thats alright, alright, alright – RT

Here’s the 2021 West Central Tribune All-Area Team – West Central Tribune

Posted: at 9:45 am

The players were masked up as a precaution for the COVID-19 pandemic. Fans were limited in numbers and many sat back from the comfort of their own homes as teams used live streaming to show their games. Sections and state quarterfinals were scattered across the state with the goal of pulling off a full season as safely as possible.

No matter where, when or how you saw the games, there was plenty of strong talent on the hardcourt across west central Minnesota. Whether you were watching the ultra-competitive Camden Conference North Divsiion or games scattered across the Central Lakes, Wright County, Central Minnesota or West Central conferences, you were in for a fun night of hoops.

With 15 spots on the West Central Tribunes All-Area Boys Basketball Team, 14 schools are represented, showing the array of talent scattered across the area. Litchfield is the only school with more than one selection.

The West Central Tribunes All-Area Boys Basketball Team was selected by the sports department based on nominations provided by area coaches.

Here is the All-Area Boys Basketball Team, presented in alphabetical order:

In the ultra-competitive Camden Conference, Riley Ashburn was voted the North divisions Most Valuable Player after pushing the Jaguars to a 13-6 record.

In 19 games this season, the 6-foot-4 forward averaged 23.3 points per game on 59% shooting. He also averaged 10.0 rebounds, 4.2 assists, 3.2 steals and 1.0 blocks per game.

An All-Area third teamer in 2020, Ashburn will resume his basketball career at Division III Bethany Lutheran College in Mankato.

Riley is a do everything type of player, said RCW head coach Matt Huhnerkoch. Not too many players can say they excelled at both offense and defense, but that was the type of player Riley is. Riley would be asked every game to guard the other teams best player for the entire game and would also find time to put up 23 points a game. But Rileys talents didnt stop there. He was also the point guard and would set up the teams offense. And then to top everything off, Riley was, no questions, the leader of the team. Riley made his teammates better.

Also making the jump from third team All-Area was Lac qui Parle Valley senior guard/forward Maverick Conn, the focal point of the Camden North champions.

Helping the Eagles to a 17-4 record and a top 10 ranking for much of the season, Conn averaged 18.7 points (61% field goals, 42% 3-pointers), 8.5 rebounds, 4.0 assists and 2.8 steals per game.

A three-time All-Camden selection, Conn is committed to play basketball at Division III Minnesota-Morris.

MACCRAY senior guard Brady Kienitz dribbles into the frontcourt during a Camden Conference game from against Lac qui Parle Valley on Monday, Feb. 8, 2021 from Lac qui Parle Valley High School in Madison. Patrick Bernadeau / West Central Tribune

A second team All-Area pick in 2020, MACCRAY senior Brady Kienitz wraps up one of the most prolific careers in school history. In 2021, Kienitz averaged 21.8 points, 6.6 rebounds, 5.7 assists and 1.8 steals per game while being named All-Camden as MACCRAY went 8-11. Kienitz owns school records for: 3-pointers in a game (8); career 3-pointers (214); 3-pointers attempts in a season (197); career 3-point attempts (559); 3-point percentage in a season (43%); free throws made in a season (130); and career free throws made (293). Kienitz will play college basketball at Division III Gustavus Adolphus in St. Peter.

Brady is the best player I have ever coached in 13 seasons working with boys varsity basketball, said Wolverines head coach Lucas Post. He has increased every critical stat line every season from his freshman year on, which is a testament to how hard he works on his game in the offseason. He was the focal point of every defense the last two seasons and still was able to average over 20 points per game in each season while shooting 45% from the field. Brady accounted for 50 percent of our teams scoring this season between his scoring and assist average. He would have set the all-time MACCRAY career scoring mark if the season hadnt been shortened due to the pandemic. Brady has done all these things offensively while guarding the opposing teams best player almost regardless of position every single game and almost always hold them under their averages.

Litchfield senior Avery Liestman (5) puts up a layup attempt during the first half of a Wright County Conference game against Rockford on Friday, Feb. 5, 2021 at Litchfield High School. Joe Brown / West Central Tribune

Making his first appearance on the All-Area squad, Litchfield senior wing Avery Liestman was a model of efficiency for the 15-6 Dragons.

A two-time unanimous Wright County Conference selection, Liestman averaged a team-high 19.4 points on 51% shooting 59% from inside the arc and 41% from 3-point range. He also averaged 5.5 rebounds and 1.0 steals per game as Litchfield reached the Section 5AA semifinals.

Liestman also came up clutch in the biggest games of the year, with 29 points against Melrose and 24 points against Glencoe-Silver Lake. In the playoffs, he hit eight 3-pointers in a 28-point effort against Dassel-Cokato, and finished with 32 points against Maranatha Christian Academy in the second round.

Avery has become an elite and efficient scorer at the high-school level, said Dragons head coach Matt Draeger. He averaged almost 20 points per game while only averaging 14 shot attempts per game. Every year we coached Avery he added something else to his game to improve his scoring efficiency. He is one of the best players Ive coached at getting open off the ball. He also improved his rebounding and defense during the year to make him a very valuable player to us on both ends of the floor. In my opinion, he is the best scorer in the area and its not close. His best games are when it mattered most. Our team will miss the leadership and encouragement he brought to our team.

BOLD senior guard Drew Sagedahl scores on an uncontested look at the basket during a West Central Conference game against Minnewaska On Jan. 19 from Bird Island. Patrick Bernadeau / West Central Tribune

The lone returning member of the All-Area first team from 2020, every opposing team was trying to slow down BOLD senior Drew Sagedahl.

That was much easier said than done. After losing All-Area teammates Gavin Vosika and Jordan Sagedahl, Drew led the area with 30.7 points per game to go with 7.4 rebounds, 4.3 assists and 2.1 steals per game as the Warriors went 5-8.

Among Drews accolades this season were an All-West Central Conference selection, a McDonald Award semifinal and a spot on the Mr. Basketball watchlist. Drew also holds school records for: points scored in a game (43); field goals made in a game (16); career 3-pointers 274; points per game in a season (30.7); free throw percentage in a season (88.1%); career free-throw percentage (42.1%); and career 3-point percentage (42.1%). He is second all time in BOLD history for career points (1,634).

Sagedahl will continue his basketball career at Division III St. Johns University.

Drew has been a scoring threat for us since his freshman year and really took on the scoring load as a senior, said Warriors head coach Jake Brustuen. He drew our opponents full attention every night and was still able to find ways to score the ball. Drew was also our leading rebounder and leader in steals. Drew was a leader by example and worked hard before, during and after practice. Drew is also a big part of our youth program and was always willing to take time to help our youth and be a leader within our program. Drew still is tied for the state record for consecutive 3-point shots made, a record he set his freshman year.

Coming back from an ACL injury that cost him his sophomore season, Belgrade-Brooten-Elrosa junior forward Ashton Dingmann bounced back in a big way. The Jaguars went 16-5 as Dingmann earned first team All-Central Minnesota Conference honors with 14.4 points, 6.4 rebounds, 2.9 assists and 1.4 steals per game.

From Jaguars head coach Chris Anderson: Ashton did a great job of triggering our fast breaks and making others around him better. Ashton has a great basketball IQ and understanding of how to adjust to different situations in the flow of the game. He is a great leader and is very coachable on and off the floor.

Corbin Froelich capped off his prep career by leading Paynesville (11-9) to back-to-back winning seasons for the first time in over 25 years. A second team All-Area selection as a junior, Froelich averaged 25.2 points, 6.9 rebounds, 2.8 assists and 2.8 steals per game while earning All-Central Minnesota Conference first team honors. He was also on the Mr. Basketball watch list. He will resume his playing career at NAIA Briar Cliff University in Sioux City, Iowa.

From Bulldogs head coach Rick Hendrickson: Corbin has a tremendous passion for basketball and he put a lot of time into improving his game. He has always been able to score in a variety of ways and presented a tough matchup for opponents with his size and quickness for a guard. He came into this season much stronger physically and shot just under 50% from the field and made 148 free throws, which was 84 more made free throws than the next closest player in the Central Minnesota Conference. If it werent for the shortened season, he would have shattered the school scoring record. Corbin helped lead the Bulldogs program to back-to-back winning seasons for the first time in over 25 years.

Making the All-Area team for the first time, Johnsrud averaged 15.1 points (44% field goal, 34% 3-pointers, 73% free throws), 2.5 assists, 4 rebounds and 2 steals per game for Minnewaska (7-11). Named team MVP, Johnsrud was named All-West Central Conference and Academic All-West Central while also earning Minnesota Boys Basketball Coaches Association Academic All-State honors.

From Lakers head coach Phil Johnsrud: Solid athlete with excellent athleticism. Extremely driven to help his team be successful. A very quiet leader by example; never wanted to outshine his teammates.

Making his first All-Area appearance, junior guard Case Mulder was a catalyst for Central Minnesota Christians first state appearance since 2017. A two-time All-Camden Conference pick, Mulder averaged 20.3 points while hitting 56% of his 2-pointers, 38% of his 3-pointers and 73% of his free throws. Mulder also averaged 4.2 assists and 1.3 steals per game as the Bluejays finished the winter with an 18-5 record.

From Bluejays head coach Ted Taatjes: Case impacted the game on both ends of the floor. Most nights he guarded the opposing teams best player and led our team in scoring and assists. He also provided the team with consistent leadership through his intensity in practice every day.

Rounding out the All-Area second team is another first timer in Benson senior guard Ben Peterson. Named the Braves team MVP and an All-West Central Conference pick, Peterson averaged 19.6 points (43.8% field goals, 34.5% 3-pointers, 81.4% free throws), 6.2 rebounds, 3.2 assists and 2.5 steals per game. Helping Benson to an 8-11 record, Peterson will play college basketball at Division III Concordia College in Moorhead.

From Braves head coach Adam Jensen: Ben is everything a coach could want in a player. He puts in a ton of time and has a deep passion for basketball. He eclipsed the 1,000-point scoring mark in a 40-point game against Morris and finished with 1,051 career points. He has an incredible ability to score in a variety of ways despite being double- and triple-teamed many games. His value to the basketball program extends beyond his performance on the court. He is very involved with our youth basketball program and is a top-notch student with a 3.7 GPA.

12.2 ppg, 5.8 rpg, 3.8 apg, 3.2 spg. All-Camden Conference. Will attend Bethel University to play college baseball.

From Fighting Saints head coach Matt Fragodt: Isaac is the player that does everything for your team. He is very good defensively and a very good rebounder. He took 24 charges this season; one game he had six charges. Offensively, he was a leader for us while we had some injuries to other players. He had to guard the best player from the other team and also score for us. His effort and heart every game will be missed.

13 ppg, 7 rpg, 2 apg, 2 bpg, 54% 2-pt, 37% 3-pt. All-Wright County. Led NLS in scoring, rebounding, assists and blocks.

From Wildcats head coach Skip Wright: Brycen had an outstanding year and established himself as one of the top players in the Wright County Conference. Hes an unselfish player who can take over a game when his team needs him to.

11.9 ppg, 6.1 rpg, 4.0 apg, 2.0 spg. Unanimous All-Wright County, Academic All-State.

From Dragons head coach Matt Draeger: Tyson does a lot for our basketball team. He has many responsibilities. He is the most important player to a team Ive ever coached at the college or high-school level. He led our team in every category you can lead a team except for scoring. He played the point guard position and led us in rebounds, assists, steals, deflections, and while turning the ball over less than one turnover per game. He is also one of the best defenders in the state, holding a number of all-state performers to single digits during the season. Ive never had a kid do more for a team than he did. Tyson is a winner and he has left his impact on our program for years to come.

16.7 ppg, 11.5 rpg, 3.5 apg, 1.5 spg, 44.5% FG, 34.5 3-pt, 80.6% FT.

From Eagles head coach Aaron Reid: Daniel would have easily cruised to the school scoring title had COVID not restricted the number of games available in 2021. He ends his high-school career as a proficient scorer and leading rebounder as one of only two seniors on the Eagles 2021 roster. He is currently uncertain if he will pursue a basketball career in college as he wants to study pre-med this fall (at Northwestern University). Daniel was a leader and example on and off the court and will be missed in the CAL conference next year.

11.2 ppg, 5.2 rpg, 2.8 apg, 1 spg. All-Central Lakes Conference. Team Offensive MVP. Will attend NAIA Dordt University in Sioux Center, Iowa to play college football.

From Cardinals head coach Matt Williams: Jacob did everything for the Cardinals this season. He handled the ball, guarded the opponents best player and almost never came out of the game. He was our unquestioned leader in the locker room and in every practice. Jacobs gifts go well beyond the basketball floor. Other players may end up with better numbers, but no player meant more to his team.

See the article here:

Here's the 2021 West Central Tribune All-Area Team - West Central Tribune

Posted in Jordan Peterson | Comments Off on Here’s the 2021 West Central Tribune All-Area Team – West Central Tribune

Peter Thiel-backed psychedelics start-up plans to raise $100 million in IPO – CNBC

Posted: at 9:44 am

Peter Thiel, co-founder of PayPal Inc.

VCG | Getty Images

ATAI Life Sciences, a biopharmaceutical company aiming to make psychedelic drugs to treat mental health disorders, announced that it is planning to raise $100 million in an initial public offering.

The Berlin-headquartered company, which counts billionaire investor Peter Thiel as one of its main backers, submitted an S-1 filing to the Securities and Exchange Commission on Tuesday.

The filing shows that ATAI has raised an aggregate of $362.3 million from private investors so far.

It is planning to sell its shares on New York's tech-focused Nasdaq market under the symbol ATAI. A date for the IPO has not been set.

Underwriters for the IPO include Credit Suisse, Citigroup, Cowen, and Berenberg.

ATAI, which describes itself as a drug development platform, was set up to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions.

The company, which has roughly 50 staff in offices across Berlin, New York and San Diego, is currently partnered with 14 companies focusing on drug development and other technologies. In exchange for a majority stake in the drugs and technologies they're developing, ATAI helps the scientists to raise money, work with the regulators, and conduct clinical trials. None of ATAI's drugs have been formally approved by regulators to date.

Thiel made a 10 million euro ($12 million) investment in ATAI through his venture firm, Thiel Capital, in November.

"ATAI's great virtue is to take mental illness as seriously as we should have been taking all illness all along," Thiel, who co-founded Palantir and PayPal, said in a statement shared with CNBC at the time. "The company's most valuable asset is its sense of urgency."

The company was founded in 2018 by entrepreneurs Christian Angermayer, Florian Brand, Lars Wilde and Srinivas Rao. It has invested in Compass Pathways, which has developed a synthetic version of the active ingredient in magic mushrooms, psilocybin.

Compass Pathways, which Thiel has also invested in, listed on the New York's NASDAQ stock exchange in September and now has a valuation of around $1.3 billion.

Read the original:

Peter Thiel-backed psychedelics start-up plans to raise $100 million in IPO - CNBC

Posted in Psychedelics | Comments Off on Peter Thiel-backed psychedelics start-up plans to raise $100 million in IPO – CNBC

Psychedelics are transforming the way we understand depression and its treatment – The Guardian

Posted: at 9:44 am

Mental illness is the 21st centurys leading cause of disability, affecting an estimated billion people across the world. Depression is the number one contributor: more than 250 million people have this condition globally. The number of people prescribed antidepressant medications, the first-line treatment for depression, increases each year, and the market for them is valued at approximately $15bn (11bn). Yet depression prevalence rates have not decreased since accurate record-keeping began. One reason for this paradox is the failure of science to adequately explain how and why depression occurs.

Psychiatry has long sought and failed to find a compelling biomedical explanation for depression. One popular idea, the serotonin hypothesis, was inspired by the observation that drugs that increase the activity of this naturally occurring brain chemical have antidepressant effects. First produced in the mid-1980s, Prozac (chemical name fluoxetine) is the most famous selective serotonin reuptake inhibitor (SSRI) antidepressant. Of these, Cipralex (escitalopram) is one of the newest and best performing.

While the serotonin hypothesis has some scientific foundation, it has been massively oversold by the pharmaceutical industry. This has stoked scepticism about one-sided, neurochemical explanations for depression, which suggest, for instance, that people are depressed because their serotonin levels are too low. The latest evidence indicates that SSRIs such as escitalopram are only marginally more effective at treating depression than a placebo, with response rates tending to average around 50-60%. Other limitations of SSRIs include poor compliance, symptoms when people stop taking them, unpleasant side-effects and a sluggish onset of antidepressant effects.

I began investigating an alternative to antidepressant medicines about 15 years ago as part of my PhD. Psilocybin, a constituent of magic mushrooms, is a classic psychedelic. When taken in high doses, it profoundly alters the quality of ones conscious awareness, producing complex visions and releasing suppressed memories and feelings. After completing a series of studies involving psilocybin, including an earlier trial of its effects among people with treatment-resistant depression, I set out to design a more rigorous test that might help to contextualise the drugs therapeutic promise. The resulting trial was completed last year, and its findings have now been published in the New England Journal of Medicine.

It was a double-blind, randomised, controlled trial involving 59 people with moderate to severe depression. They were randomly allocated to one of two treatment groups: one in which the main treatment was a six-week course of the conventional SSRI antidepressant, escitalopram, and another in which the main treatment was two high-dose psilocybin therapy sessions.

Those in the escitalopram group did about as well as one would expect, based on previous SSRI trial data and the relatively short, six-week course. Across four different measures of depressive symptoms, the average response rate to escitalopram at the end of the trial was 33%. In comparison, psilocybin worked more rapidly, decreasing depression scores as early as one day after the first dosing session. At the end of the trial, the average response rate to psilocybin therapy was more than 70%.

While we suspected that psilocybin might perform well compared to the SSRI, we had not expected it to perform as well as it did. In fact, the initial main hypothesis for this trial was that the psilocybin therapy would have superior effects on psychological wellbeing, but not on depression severity scores. This prediction was generally supported, but people in the psilocybin group also showed evidence of greater improvements across most depression measures, as well as anxiety symptoms, work and social functioning, suicidal feelings and the ability to feel emotion and pleasure.

Both groups experienced similar levels of side-effects, but the escitalopram group experienced worse drowsiness, dry mouth, sexual dysfunction and anxiety. In the psilocybin group, the most prevalent side-effect was a mild to moderate headache one day after dosing. Six-month follow-up work is now under way to test our prediction that the positive effects seen in the psilocybin group will be longer lasting.

So why does psilocybin appear to be a more successful treatment for depression than a typical antidepressant? Brain imaging data from the trial, alongside the psychological data we collected, appears to show that while SSRIs dampen emotional depth by reducing the responsiveness of the brains stress circuitry, helping to take the edge off depressive symptoms, psilocybin seems to liberate thought and feeling. It does this by dysregulating the most evolutionarily developed aspect of our brain, the neocortex. When this liberation occurs alongside professional psychological support, the most common outcome is a renewed breadth of perspective. Psychedelic therapy seems to catalyse a type of psychological growth that is conducive to mental health, overlapping in many respects with spiritual growth.

The most exciting aspect of this trial is a sense that we are on the verge of a paradigm shift in mental healthcare linked to an improved understanding of the origins of depression, and how we can most effectively treat it. In my view, this shift will take us away from an outdated and myopic drug-alone perspective that has dominated psychiatry for several decades, and towards a multi-level biopsychosocial model. This model sees the symptoms of depression as an adaptive response to adversity, with decipherable albeit complex psychosocial causes. Psychedelics can treat depression by activating powerful brain states that have evolved in humans to catalyse deep psychological change. When these hyper-plastic states are combined with a nurturing environmental context, defensive habits of mind and behaviour can undergo a healthy, potentially enduring revision.

These ideas arent confined to the academy. Since I wrote about developments in psychedelic medicine for the Guardian last year, the US state of Oregon has voted in favour of legalising psilocybin therapy, a senate bill has been introduced to decriminalise psychedelic drugs in California, and policies are also being reviewed in New York, Washington DC, New Jersey, Florida, Canada, Australia and the UK. The Australian government has pledged A$15m (8.5m) to psychedelic research, while two new research centres dedicated to studying psychedelic medicine have been announced at major US universities. Of course, our study certainly isnt a licence for people to self-medicate. But these are exciting developments and show that governments are recognising the benefits of psychedelic therapies.

Many obstacles have already slowed the progress of psychedelic medicine, and there will doubtless be more, from litigation issues to moral objections. If were to achieve a population-level improvement in psychological wellbeing, this road wont be easy. Despite the recent landmark trial, I do sometimes wonder if we will make it at all. One thing I am more certain of, however, is that we must try.

Follow this link:

Psychedelics are transforming the way we understand depression and its treatment - The Guardian

Posted in Psychedelics | Comments Off on Psychedelics are transforming the way we understand depression and its treatment – The Guardian

Psychedelics As A Potential Form Of Treatment For Traumatic Brain Injuries – Yahoo Finance

Posted: at 9:44 am

In recent years, there has been a re-emergence in the study of psychedelic drugs as a form of therapeutic treatment. After their height in popularity during the 1950s to early 1970s, psychedelics are now re-entering the medical field. Currently, psychedelics such as LSD, psilocybin, and MDMA among others are being studied for their effectiveness in treating patients diagnosed with anxiety, depression, addiction, PTSD, and traumatic brain injuries.

While recent research on psychedelics as a form of therapeutic treatment is still under development, research centers such as the NYU Langone Center for Psychedelic Medicine and Johns Hopkins Medicine (alongside multiple others) are allocating resources towards the study of psychedelics in medicine.

For example, the NYU Langone Center for Psychedelic Medicine is currently studying the use of psilocybin to treat alcohol use disorder as well as major depressive disorder, and MDMA-assisted psychotherapy for the treatment of PTSD.However, looking particularly at psychedelics potential to treat traumatic brain injuries, multiple therapeutic and psychedelics companies such as Mind Cure Health Inc (OTCQB: MCURF), Revive Therapeutics Ltd (OTC: RVVTF) and Champignon Brands Inc (OTC: SHRMF) are currently dedicating resources towards this research effort.

What Is A TBI?A traumatic brain injury (TBI) is defined as a disruption in the normal function of the brain, typically caused by a jolt, bump or blow to the head. The severity of a TBI ranges from a mild case such as a concussion to severe, a coma.

For milder cases, side effects from a TBI-related injury can last up to a few days or for the rest of a patients life. Some of these side effects include issues related to emotional functioning and impairments related to memory, vision or hearing.

Some of the leading causes for traumatic brain injuries include falls, motor vehicle accidents, being struck by or against an object, and intentional self-harm.

Story continues

According to the CDC, traumatic brain injuries are currently one of the leading causes of death and disability in the U.S. as an estimated 1.5 million Americans sustain a TBI every year and this number is only expected to rise.

The CDC found that the number of TBI-related emergency department visits, hospitalizations, and deaths in the U.S. increased by 53% from 2006 to 2014. In the last reported year, an average of 155 people died each day from a TBI-related injury.

A Potential Treatment OpportunityMental health and wellness company MINDCURE recently announced its efforts towards researching psychedelics for the treatment of TBIs.The company will be using its bioinformatics platform, Psycollage, to help aid them in their research.

Through Psycollage, the company identified opportunities for the treatment of traumatic brain injuries using a psychoactive substance called ibogaine.

MINDCURE believes that ibogaine could be crucial for the treatment of brain trauma and neuropathic pain, noting that the substance has been thought to stimulate the growth of new dopamine neurons and repair and reset the brain's reward system.

Ibogaine, which is extracted from the iboga shrub, has been used by West African communities for centuries in both rituals and healing ceremonies. Yet, this psychedelic did not make its way into the western world until 1864.

In 1970, the FDA classified ibogaine as a Schedule I drug alongside other psychoactive drugs such as psilocybin and LSD. However, in recent years with the resurgence of psychedelics in therapeutic research the regulatory landscape is once again becoming more favorable.

To help facilitate this research, the company has brought on Dr. Dan Engle who is Board Certified in Psychiatry and Neurology, as the companys Primary Investigator Consultant.

"MINDCURE is fortunate that Dr. Engle has chosen to bring his expertise and clinical experience with trauma and head injury to lead MINCURE's research efforts," said President and CEO Kelsey Ramsden. "Dr. Engle is a trusted resource whose guidance will be pivotal in leading this transformative research program. TBI issues not only affect individuals but also can have lasting effects on families and communities."

For additional national statistics and to learn more about traumatic brain injuries, visit https://www.cdc.gov/TraumaticBrainInjury/index.html.

See more from Benzinga

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Excerpt from:

Psychedelics As A Potential Form Of Treatment For Traumatic Brain Injuries - Yahoo Finance

Posted in Psychedelics | Comments Off on Psychedelics As A Potential Form Of Treatment For Traumatic Brain Injuries – Yahoo Finance

Psychedelic Drugs Market Size Is Projected To Reach $10.75 Billion By 2027 – PRNewswire

Posted: at 9:44 am

PALM BEACH, Fla., April 21, 2021 /PRNewswire/ -- The psychedelics industry has entered the spotlight! The rapidly increasing acceptance of psychedelic treatments is creating a strong demand from therapists and patients for access to the new products and therapies. Industry reports for rise in revenues all seem to be higher than the previous report. A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. Active companies in the markets this week include: Mind Cure Health Inc. (OTCQB: MCURF) (CSE: MCUR),Mind Medicine (MindMed) Inc.(OTCQB: MMEDF) (NEO: MMED), Numinus Wellness Inc. (OTCPK: LKYSF)(TSXV: NUMI), Field Trip Health Ltd. (OTCQX: FTRPF) (CSE: FTRP), Cybin, Inc. (OTCQB: CLXPF) (NEO: CYBN).

The Data Bridge report also said that: "The psychedelic drugs are used to enhance or change sensory perceptions, energy levels, thought processes, and to facilitate spiritual experiences. Psychedelic drugs can be categorized into dissociative drugs (such as PCP), empathogens and serotonergic (classic hallucinogens) (such as LSD). These drugs are used in the treatment of major depressive disorder, treatment-resistant depression, panic disorder, post-traumatic stress disorder, and opiate addiction among others. Psychedelic drugs market has increased with increased number of psychedelic drugs as compared to the past few years and increasing prevalence of depression and mental disorders in the U.S. Growing acceptance of psychedelic drugs for treating depression is also increasing market value as the psychedelic drugs has repetitively proven its high rates of effectiveness for treatment for nicotine dependence, alcohol dependence, anxiety associated terminal illness and chronic PTSD as compared to other antidepressants. Currently, different research studies are taking place that are expected to provide a competitive advantage for new and innovative therapeutic manufacturers with competitive psychedelic drugs and methods to develop, define psychedelic drugs, and various other opportunities in the U.S. psychedelic market."

Mind Cure Health Inc. (CSE: MCUR.CNQ) (OTCQB: MCURF) BREAKING NEWS: MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions - Mind Cure Health Inc,a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce a partnership with LUCID Inc. ("LUCID"). LUCID's mission is to help people optimize their mental wellness through music, and they will be designing custom psychedelic music experiences for iSTRYM.

After announcing its data partnership with Speak Ai last week, MINDCURE continues to integrate world-class technologies into and create proprietary experiences within iSTRYM, its psychedelics digital therapeutics platform. LUCID's platform is a key differentiator for iSTRYM as therapists and patients seek out scientifically validated tools to enhance the effectiveness of psychedelic-assisted therapies. It will enable the therapist to alter the music within a therapy session based on real-time feedback and data collected from the patient, all within iSTRYM.

"We look forward to working with MINDCURE's team and bringing our expertise to psychedelic-assisted therapies," said Zach McMahon, LUCID CEO and Co-Founder. "Our team will be researching and taking into consideration the therapeutic targets and mechanisms of action associated with each psychedelic while leveraging our machine learning systems to optimize the music experiences in iSTRYM for personalization and efficacy."

Music has been shown to be effective as a stress and anxiety management tool and also has shown efficacy for diverse outcomes, including chronic and acute pain. Listening to music evokes a wide range of emotions, and because of this, music listening has been a component of several psychological interventions in the area of anxiety and depression, such as post-traumatic stress disorder. With this integration, therapists will have access to music designed for psychedelic-assisted therapies and specific psychedelic compounds that is changing in real-time based on patient feedback, AI and collected data to deepen or alter the experience.

"We are building first-of-its-kind functionality by pairing AI-driven music scapes with a therapist's art of directing the experience for patients in psychedelic-assisted therapy sessions," said Kelsey Ramsden, MINDCURE President and CEO. "Integrating LUCID will further enhance iSTRYM's capabilities and its potential as the validated backbone of the roll-out of psychedelic therapy and trusted wingman for therapists and patients who want a digital therapeutic partner that allows for quantified medicine with personalization at scale." CONTINUED To read this and more news for Mind Cure Health, please visit https://www.financialnewsmedia.com/news-mcur/

Other recent developments in the markets include:

MindMed (OTCQB: MMEDF) (NEO: MMED), a leading clinical-stage psychedelic medicine biotech company, recently announced the publication of the first study on MDMA dosing optimization using personalized medicine. The study took place at the University Hospital Basel Liechti Lab, inBasel, Switzerland. This study provides the first scientific data for predicting responses to MDMA and optimizing dosing. This may maximize the potential beneficial therapeutic effects while reducing adverse responses when treating medical conditions.

The study used data from 194 MDMA administrations in ten randomized placebo-controlled studies in healthy subjects conducted by the Liechti Lab at the University HospitalBasel, Switzerland. Key findings of the study suggest: The dose of MDMA can be optimized using predictors known before dosing including body weight, sex, age, genetics, personality trait measures, and mood before drug administration; The dose of MDMA per kg body weight of the treated person best predicted the MDMA concentrations in the body and also mainly determined the acute subjective response to MDMA.

Numinus Wellness Inc. (OTCPK: LKYSF)(TSXV: NUMI) provides solutions to develop and deliver psychedelic-assisted psychotherapy and transform the mental health landscape. The company operates in two divisions, Salvation Botanicals and Numinus Health. The Salvation Botanicals division offers laboratory services, such as cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics; and full suite testing and custom testing of cannabis. The Numinus Health division provides supportive therapies and technologies to heal, connect, and grow with a focus on treating mental health and substance abuse; and services for psychotherapy, counselling, neurofeedback, physiotherapy, and other therapies. This division also offers training, facilities, and other operational resources to practitioners. The company is headquartered in Vancouver, Canada.

Field Trip Health Ltd. (OTCQX: FTRPF) (CSE: FTRP), a leader in the development and delivery of psychedelic therapies, recently reported its third fiscal quarter results for the three and nine months ended December 31, 2020. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

Joseph del Moral, Field Trip's CEO, said, "We are making rapid progress maximizing value for shareholders by building out Field Trip's complementary business lines that focus on both the development and the delivery of psychedelic therapies. Our deeply integrated platform combines drug and product developments, psychedelic-enhanced therapy and technology-enabled virtual care solutions. All the components work in concert with each other to increase our understanding of the therapeutic value of psychedelics and to deliver them to patients that need them most. With our early-mover advantage, a strong cash position, and a strong and growing reputation as thought leaders in the industry, we are well-positioned to propel our growth in the emerging market of psychedelic therapy."

Cybin Inc.(OTCQB: CLXPF) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, recently announced plans to advance the pre-clinical work for its orally dissolving tablet ("ODT") formulation of CYB003 and its inhaled formulation of CYB004, two of the Company's deuterated tryptamine development candidates. These studies are part of the required U.S. Food and Drug Administration ("FDA") enabling trials for investigational new drug applications ("INDs").

Upon successful completion, the results of the IND-enabling studies will be included in the submissions to the FDA, as well as to other regulatory bodies, such as Health Canada and European Medical Association ("EMA"). The candidates would then advance into Phase 1 human clinical trials for specified psychiatric conditions. Labcorp Drug Development will serve as the pre-clinical research organization for Cybin.

DISCLAIMER:FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein.FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers.Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Mind Cure Health Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:[emailprotected]+1(561)325-8757

SOURCE FinancialNewsMedia.com

Read the original here:

Psychedelic Drugs Market Size Is Projected To Reach $10.75 Billion By 2027 - PRNewswire

Posted in Psychedelics | Comments Off on Psychedelic Drugs Market Size Is Projected To Reach $10.75 Billion By 2027 – PRNewswire

Study: Tripping might not be required for psychedelic therapy – Big Think

Posted: at 9:44 am

Due to stigma, their illegal status and difficulty in finding control groups, research with psychedelics has been a challenge. But research increasingly shows that this class of drug has legitimate medicinal uses, and they may be just as good or even better than more traditional therapies.

Now, the Centre for Psychedelic Research at Imperial College London reports in the New England Journal of Medicine that when pitted against escitalopram (brand name: Lexapro), psilocybin was as effective as the popular SSRI (selective serotonin reuptake inhibitor) in treating moderate to severe depression. Perhaps most significantly, these results were obtained when comparing 6 weeks of daily doses of escitalopram to just two administrations of psilocybin.

Robin Carhart-Harris, head of the center who has published over 100 papers on psychedelics, is confident this study represents another step forward in applying psychedelics to mental health treatment protocols while also reducing fears a lot of citizens have around these substances. In a press release, he said:

"One of the most important aspects of this work is that people can clearly see the promise of properly delivered psilocybin therapy by viewing it compared with a more familiar, established treatment in the same study. Psilocybin performed very favorably in this head-to-head."

Credit: Robin Carhart-Harris et al, NEJM, 2021.

As depicted above, the phase 2 clinical trial included 59 volunteers. The escitalopram (control) group received six weeks of daily escitalopram in addition to two tiny (1-mg) doses of psilocybin a dose so low that it is unlikely to produce hallucinogenic effects. The psilocybin (experimental) group received two 25-mg doses of psilocybin three weeks apart with placebo given on all the other days.

At the end of the study, both groups saw a decrease in depressive symptoms, though the results were not statistically significant. (That isn't necessarily bad because if the two drugs have similar effects, then they would not produce statistically significant results. Still, a larger study is needed to confirm that psilocybin is "just as good as" escitalopram.)

Additionally, several other outcomes favored psilocybin over escitalopram. For instance, 57 percent in the psilocybin group saw a remission of symptoms compared to 28 percent in the escitalopram group. This result was significant.

As psychedelics become decriminalized and potentially legalized for therapeutic use, however, a large population of people might desire the antidepressant effects without the hallucinations. For example, the psychedelic ibogaine may be useful for treating addiction, so the company Mindmed is developing an analog that works without producing the unwanted hallucinogenic side effects.

A new research article, published in the journal PNAS, investigated the antidepressant effects of psilocybin on a group of chronically stressed mice. (Under immense stress, mice develop something resembling human depression.) As with humans, depressed mice lose a sense of joy, which can be assessed by determining their preference for sugar water over tap water. Normal mice prefer sugar water, but depressed mice simply don't care.

Once the mice were no longer juicing up on the sweetened water, the team dosed them with psilocybin alongside a drug called ketanserin, a 5-HT2A serotonin receptor antagonist that eliminates psychedelic effects. Within 24 hours of receiving the dose, the mice were rushing back to the sugar water, indicating that tripping is not necessary for psilocybin to work as an antidepressant.

While the team is excited about these results, they realize it needs to be replicated in a different population.

"The possibility of combining psychedelic compounds and a 5-HT2AR antagonist offers a potential means to increase their acceptance and clinical utility and should be studied in human depression."

Photo: Cannabis_Pic / Adobe Stock

Psychedelics such as psilocybin and LSD have a long track record of efficacy in clinical trials and anecdotal experiences. Almost all volunteers of the famous Marsh Chapel experiment claimed their experience on Good Friday in 1962 was one of the most significant events of their lives and this was a quarter-century after the fact. A more recent, controlled study found that a single dose of psilocybin showed antidepressant effects six months later.

Proponents of macrodosing and ritualistic experiences sometimes argue that the full-blown mystical trip is the therapy, though this is anecdotal, not clinical research. As the Maryland team noted, a number of people are contraindicated for psychedelics, whether through a family history of schizophrenia or current antidepressant treatments.

Senior author Scott Thompson is excited for future research on this topic. As he said of his team's findings:

"The psychedelic experience is incredibly powerful and can be life-changing, but that could be too much for some people or not appropriate These findings show that activation of the receptor causing the psychedelic effect isn't absolutely required for the antidepressant benefits, at least in mice."

Hopefully, with more research occurring in psychedelics than even in the 1950s (when studies predominantly relied on anecdotal evidence and little government support), the longstanding stigmatization of psychedelics is beginning to recede. This could open up new possibilities for both clinical research and, for those curious about the ritual effects, a continuation of introspective experiences.

--

Stay in touch with Derek on Twitter and Facebook. His most recent book is "Hero's Dose: The Case For Psychedelics in Ritual and Therapy."

From Your Site Articles

Related Articles Around the Web

Continue reading here:

Study: Tripping might not be required for psychedelic therapy - Big Think

Posted in Psychedelics | Comments Off on Study: Tripping might not be required for psychedelic therapy – Big Think